Alzamend Neuro, Inc.
50 W. Broadway
Suite 300
Salt Lake City
Utah
84101
United States
Tel: 949-346-5822
Website: https://alzamend.com/
About Alzamend Neuro, Inc.
Alzamend Neuro is a development stage biotechnology company which has licensed a patented mutant peptide developed by Dr. Chuanhai Cao at the college of Pharmacy of the University of South Florida (USF) and USF- Health Byrd Alzheimer’s Institute to develop a cell based therapeutic vaccine as an immunotherapy to prevent or slowdown Alzheimer’s disease. This therapy is not only target on the pathological molecule that is associated to AD, but also is able to fix the impaired immune system associated to AD developmentYEAR FOUNDED:
2016
LEADERSHIP:
CEO: Phil Mansour
CTO: William B. Horne
Chairman: Milton “Todd” Ault
CAREER:
Please click here for Alzamend Neuro's job opportunities.
64 articles about Alzamend Neuro, Inc.
-
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients
12/11/2023
Alzamend Neuro, Inc. today announced receipt of a “Study May Proceed” letter from the U.S. Food and Drug Administration (“FDA”) for the initiation of study AL001-PTSD01, a Phase IIA clinical study of AL001 for treatment of patients with PTSD.
-
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients
11/20/2023
Alzamend Neuro, Inc. announced receipt of a “Study May Proceed” letter from the U.S. Food and Drug Administration for the initiation of study AL001-MDD01, a Phase IIA clinical study of AL001 for treatment of patients with MDD.
-
Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
11/16/2023
Alzamend Neuro, Inc. today announced that it has received a notification letter (the “ Compliance Notice ”) from the Listing Qualifications Staff of the Nasdaq Stock Market, LLC informing Alzamend that it has regained compliance with Nasdaq Listing Rule 5550(a)(2).
-
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001
11/13/2023
Alzamend’s recently completed Phase IIA Study of AL001 in Alzheimer’s patients and healthy subjects showed a benign safety profile and identified a candidate dose that is unlikely to require therapeutic drug monitoring.
-
Alzamend Neuro Announces Reverse Stock Split
10/30/2023
Alzamend Neuro, Inc. today announced that Alzamend’s board of directors approved a one-for-fifteen reverse stock split of Alzamend’s common stock.
-
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001
10/23/2023
Alzamend Neuro, Inc. today announced that it has submitted an investigational new drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) for the initiation of study AL001-MDD01, a Phase IIA plasma/brain pharmacokinetics clinical study of AL001 for adjunctive treatment of patients with MDD.
-
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients
10/2/2023
Alzamend Neuro, Inc. today announced receipt of a “Study May Proceed” letter from the U.S. Food and Drug Administration (“FDA”) for the initiation of study AL001-BD01, a Phase IIA clinical study of AL001 for BD type 1.
-
Alzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement
9/22/2023
Alzamend Neuro, Inc. today announced that it received notice from the Nasdaq Hearings Panel (the “ Hearings Panel ”) of The Nasdaq Stock Market LLC (“ Nasdaq ”), which granted Alzamend’s request for continued listing on The Nasdaq Capital Market, subject to Alzamend’s satisfaction of the minimum $1.00 bid price requirement by November 15, 2023.
-
Alzamend Neuro Announces Positive Phase IIA Clinical Trial Results for AL001
6/22/2023
Alzamend plans two Phase II clinical trials to investigate the safety and efficacy of AL001 for patients with mild to moderate Alzheimer’s disease.
-
Alzamend Neuro CEO Stephan Jackman to Participate on the “Mental Health, More Critical Than Ever” Panel at the Maxim Group’s Virtual Healthcare Conference
6/13/2023
Alzamend Neuro, Inc. announced that CEO Stephan Jackman will participate as a panelist at the upcoming Maxim Group Virtual Healthcare Conference, to be held between June 20 –22, 2023.
-
Altasciences Completes Clinical Portion of Alzamend Neuro’s Phase IIa Multiple Ascending Dose Clinical Trial for Treatment of Dementia Related to Alzheimer’s
4/18/2023
Altasciences is proud to support Alzamend Neuro, Inc. (Alzamend) in advancing a novel treatment for dementia related to Alzheimer’s disease (Alzheimer’s).
-
Alzamend Neuro Announces the Initiation of a Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
4/3/2023
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”) today announced the initiation of a phase I/IIA clinical trial for its immunotherapy vaccine (ALZN002) to treat mild to moderate dementia of the Alzheimer’s type.
-
KILL Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
4/3/2023
Alzamend Neuro, Inc. requests that their press release NewsItemId: 20230403005455 “Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type” be killed.
-
Alzamend Neuro Announces Completion of Clinical Portion of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
3/22/2023
Alzamend Neuro, Inc. today announced the completion of the clinical portion of its Phase IIA multiple ascending dose (“ MAD ”) study for dementia related to Alzheimer’s.
-
Alzamend Neuro Reports Third Fiscal Quarter Financial Results and Provides a Business Update
3/16/2023
Alzamend Neuro, Inc. today announced financial results for the third quarter ended January 31, 2023 and provided an update on its clinical operations.
-
Alzamend Neuro to Present at Sequire Biotechnology Conference
1/26/2023
Alzamend Neuro, Inc. today announced that it will be presenting virtually at the upcoming Sequire Biotechnology Conference on Thursday, February 2, 2023.
-
Alzamend Neuro Partners With Biorasi to Conduct a First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase I/IIA Clinical Trial
1/4/2023
Study to Assess the Safety, Tolerability, and Efficacy of Autologous Amyloid Beta Mutant Peptide-Pulsed Dendritic Cells (ALZN002) in Subjects With Mild-to-Moderate Dementia of the Alzheimer's Type.
-
Alzamend Neuro Partners With the Miller School of Medicine, Interdisciplinary Stem Cell Institute at the University of Miami for ALZN002 Phase I/IIA Immunotherapy Vaccine Clinical Trial to Treat Mild to Moderate Dementia of the Alzheimer’s Type
12/28/2022
Alzamend Neuro, Inc. announced that it is partnering with the Miller School of Medicine, Interdisciplinary Stem Cell Institute at the University of Miami for its Phase I/IIA clinical trial of ALZN002, a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s.
-
Alzamend Neuro CEO Stephan Jackman to Appear on Fox Business Network to Discuss Therapeutic Pipeline
11/15/2022
Alzamend Neuro, Inc. today announced that CEO Stephan Jackman will be interviewed on the Fox Business Network news channel on Wednesday, November 16, 2022.
-
Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
10/31/2022
Alzamend Neuro, Inc. today announced receipt of a “Study May Proceed” letter from the U.S. Food and Drug Administration (“FDA”) for a phase I/IIA clinical trial under its Investigational New Drug (“IND”) application for an immunotherapy (ALZN002) to treat mild to moderate dementia of the Alzheimer’s type.